COVID-19 is linked to metabolic abnormalities and mitochondrial malfunctioning. According to a new study, recovery from COVID infection can be achieved faster by adopting a treatment using metabolic activators.
COVID-19 recovery can be enhanced by the treatment with metabolic activators, suggests a new study. While the average duration of recovery for this infection is between 14 to 21 days, the researchers of the current study highlighted that the use of combined metabolic activators (CMAs) would give a 3.5-day reduction in recovery time . Researchers from the KTH Royal Institute of Technology partnered with the Sahlgrenska Academy in Gothenburg and King's College of London to conduct this phase-III clinical study.
‘Combined Metabolic Activators promote metabolic functions and enhance disease recovery. COVID patients who received it had a 3.5-day reduction in recovery time.’
The findings of the study were published in the journal Advanced Science . What metabolic activators have to do with COVID?
Although COVID-19 is generally presented as a viral disease affecting the respiratory tract, it is also associated with many metabolic abnormalities and malfunction of mitochondria in the cells. The research team probed this particular area further and arrived at the solution of using combined metabolic activators to treat mild-to-moderate COVID infections.
They tested the effect of four glutathione and NAD+ precursors namely nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate in restoring the metabolic functions of COVID patients .
"Dysfunctional mitochondria have been implicated in worsened progression for Covid-19, and we are pleased to find that the combination of these metabolic activators helps to remedy the stress put on the body of an infected patient," said Adil Mardinoglu, the study's lead author.
Advertisement
The trial enrolled 309 outpatients at Umraniye Teaching and Research Hospital of Istanbul. Along with the standard care, the patients received either CMAs or placebo drugs twice a day for 14 days. Their clinical status was regularly evaluated by telephone check-ins.
Advertisement
"Our phase three data shows that metabolic activators significantly improve the recovery, liver health, and markers of inflammation of patients with COVID-19," said author Adil Mardinoglu, regarding the other benefits of using CMAs.
Source-Medindia